

Massimo Falconi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2229145/publications.pdf>

Version: 2024-02-01

586
papers

49,157
citations

2795

94
h-index

2027

205
g-index

595
all docs

595
docs citations

595
times ranked

29169
citing authors

#	ARTICLE	IF	CITATIONS
1	Exâ€vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. DEN Open, 2023, 3, .	0.5	2
2	Postpancreatectomy Acute Pancreatitis (PPAP). Annals of Surgery, 2022, 275, 663-672.	2.1	56
3	Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma. Annals of Surgery, 2022, 276, 378-385.	2.1	50
4	The impact of preoperative anemia on pancreatic resection outcomes. Hpb, 2022, 24, 717-726.	0.1	1
5	EUS-guided gallbladder drainage and subsequent peroral endoscopic cholecystolithotomy: A tool to reduce chemotherapy discontinuation in neoplastic patients?. VideoGIE, 2022, 7, 120-127.	0.3	8
6	Pancreaticoduodenectomy in octogenarians: The importance of â€œbiological ageâ€ on clinical outcomes. Surgical Oncology, 2022, 40, 101688.	0.8	7
7	The impact of nutritional status on pancreatic cancer therapy. Expert Review of Anticancer Therapy, 2022, 22, 155-167.	1.1	8
8	Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module). Journal of Neuroendocrinology, 2022, 34, e13097.	1.2	5
9	How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery. Current Oncology Reports, 2022, 24, 227-239.	1.8	2
10	Surgery for Intraductal Papillary Mucinous Neoplasms of the Pancreas: Preoperative Factors Tipping the Scale of Decision-Making. Annals of Surgical Oncology, 2022, 29, 3206-3214.	0.7	13
11	Early biochemical predictors of clinically relevant pancreatic fistula after distal pancreatectomy: a role for serum amylase and C-reactive protein. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 5431-5441.	1.3	10
12	Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Critical Reviews in Oncology/Hematology, 2022, 169, 103571.	2.0	17
13	Clinical and economic validation of grade B postoperative pancreatic fistula subclassification. Surgery, 2022, 171, 846-853.	1.0	3
14	Differential EUS findings in focal type 1 autoimmune pancreatitis and pancreatic cancer: A proof-of-concept study. Endoscopic Ultrasound, 2022, 11, 216.	0.6	5
15	Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer: multicentre study. British Journal of Surgery, 2022, 109, 617-622.	0.1	11
16	Survival after active surveillance <i>versus</i> upfront surgery for incidental small pancreatic neuroendocrine tumours. British Journal of Surgery, 2022, 109, 733-738.	0.1	4
17	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Network Open, 2022, 5, e220290.	2.8	21
18	Feasibility of therapeutic endoscopic ultrasound in the bridge-to-surgery scenario: The example of pancreatic adenocarcinoma. World Journal of Gastroenterology, 2022, 28, 976-984.	1.4	3

#	ARTICLE	IF	CITATIONS
19	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13105.	1.2	12
20	The use of ace inhibitors influences the risk of progression of BD-IPMNs under follow-up. <i>Pancreatology</i> , 2022, , .	0.5	1
21	Diagnosis and treatment of exocrine pancreatic insufficiency in chronic pancreatitis: An international expert survey and case vignette study. <i>Pancreatology</i> , 2022, 22, 457-465.	0.5	14
22	Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1994-2001.	0.5	5
23	Preoperative risk stratification of postoperative pancreatic fistula: A risk-tree predictive model for pancreatoduodenectomy. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2022, 26, S66-S66.	0.1	0
24	Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?. <i>Journal of Clinical Medicine</i> , 2022, 11, 2658.	1.0	3
25	Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases. <i>Endocrine Pathology</i> , 2022, 33, 274-288.	5.2	5
26	Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. <i>Cancers</i> , 2022, 14, 2501.	1.7	7
27	Pancreatic resections for benign intraductal papillary mucinous neoplasms: Collateral damages from friendly fire. <i>Surgery</i> , 2022, 172, 1202-1209.	1.0	4
28	The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 7063-7073.	0.7	2
29	A polymorphic variant in telomere maintenance is associated with worrisome features and high-risk stigmata development in IPMNs. <i>Carcinogenesis</i> , 2022, 43, 728-735.	1.3	5
30	Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An International Multicenter Propensity Score-matched Study. <i>Annals of Surgery</i> , 2021, 274, e1001-e1007.	2.1	17
31	Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome â€“ An International Consensus Statement. <i>Neuroendocrinology</i> , 2021, 111, 609-630.	1.2	63
32	Evidence of a common cell origin in a case of pancreatic mixed intraductal papillary mucinous neoplasmâ€“neuroendocrine tumor. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1215-1219.	1.4	13
33	The impact of minimally invasive surgery on hospital readmissions, emergency department visits and functional recovery after distal pancreatectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 5740-5751.	1.3	7
34	A four-step method to centralize pancreatic surgery, accounting for volume, performance and access to care. <i>Hpb</i> , 2021, 23, 1095-1104.	0.1	12
35	Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2021, 111, 273-287.	1.2	32
36	Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2021, 111, 728-738.	1.2	13

#	ARTICLE	IF	CITATIONS
37	Outcomes after distal pancreatectomy for neuroendocrine neoplasms: a retrospective comparison between minimally invasive and open approach using propensity score weighting. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 165-173.	1.3	15
38	Update on gastroenteropancreatic neuroendocrine tumors. <i>Digestive and Liver Disease</i> , 2021, 53, 171-182.	0.4	45
39	Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?. <i>Surgery</i> , 2021, 169, 403-410.	1.0	18
40	The Oncologic Impact of Pancreatic Fistula After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma of the Body and the Tail: A Multicenter Retrospective Cohort Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 3171-3183.	0.7	6
41	ASO Author Reflections: Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 2323-2324.	0.7	1
42	Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma: Legend or Scientific Evidence?. <i>Annals of Surgical Oncology</i> , 2021, 28, 2312-2322.	0.7	5
43	Management of Locally Advanced Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 273, 1173-1181.	2.1	47
44	Reappraisal of a 2-Cm Cut-off Size for the Management of Cystic Pancreatic Neuroendocrine Neoplasms. <i>Annals of Surgery</i> , 2021, 273, 973-981.	2.1	10
45	Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms. <i>Diagnostics</i> , 2021, 11, 192.	1.3	20
46	R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4602-4612.	0.7	18
47	New Surgical Strategies. , 2021, , 113-128.		0
48	Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study. <i>European Journal of Internal Medicine</i> , 2021, 84, 63-67.	1.0	18
49	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. <i>European Journal of Cancer</i> , 2021, 144, 200-214.	1.3	12
50	High sensitivity of ROSE-supported ERCP-guided brushing for biliary strictures. <i>Endoscopy International Open</i> , 2021, 09, E363-E370.	0.9	11
51	ASO Author Reflections: R Status Is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4613-4614.	0.7	1
52	CT-derived radiomic features to discriminate histologic characteristics of pancreatic neuroendocrine tumors. <i>Radiologia Medica</i> , 2021, 126, 745-760.	4.7	72
53	Before sentinel bleeding: early prediction of postpancreatectomy hemorrhage (PPH) with a CT-based scoring system. <i>European Radiology</i> , 2021, 31, 6879-6888.	2.3	7
54	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021, 146, 56-73.	1.3	120

#	ARTICLE	IF	CITATIONS
55	Endoscopic ultrasound-guided gastrojejunostomy does not prevent pancreaticoduodenectomy after long-term symptom-free neoadjuvant treatment. <i>Endoscopy</i> , 2021, , .	1.0	5
56	Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development. <i>Surgery</i> , 2021, 169, 708-720.	1.0	22
57	Low-frequency of RABL3 pathogenetic variants in hereditary and familial pancreatic cancer. <i>Digestive and Liver Disease</i> , 2021, 53, 519-521.	0.4	2
58	Screening for pancreatic cancerâ€”a compelling challenge. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 264-266.	0.7	3
59	Impact of care pathway adherence on recovery following distal pancreatectomy within an enhanced recovery program. <i>Hpb</i> , 2021, 23, 1815-1823.	0.1	7
60	Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology. <i>Hpb</i> , 2021, 23, 1666-1673.	0.1	15
61	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	0
62	Portal vein resection during pancreaticoduodenectomy for pancreatic neuroendocrine tumors. An international multicenter comparative study. <i>Surgery</i> , 2021, 169, 1093-1101.	1.0	12
63	Understanding the Meaning of Recovery to Patients Undergoing Abdominal Surgery. <i>JAMA Surgery</i> , 2021, 156, 758-765.	2.2	31
64	Proclivity to Explore Locally Advanced Pancreas Cancer Is Not Associated with Surgeon Volume. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2562-2571.	0.9	2
65	Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). <i>Annals of Surgical Oncology</i> , 2021, 28, 7506-7517.	0.7	25
66	Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1258-1266.	0.5	5
67	Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. <i>Annals of Surgery</i> , 2021, 274, 481-490.	2.1	22
68	Indications to total pancreatectomy for positive neck margin after partial pancreatectomy: a review of a slippery ground. <i>Updates in Surgery</i> , 2021, 73, 1219-1229.	0.9	3
69	Preoperative risk stratification of postoperative pancreatic fistula: A risk-tree predictive model for pancreatoduodenectomy. <i>Surgery</i> , 2021, 170, 1596-1601.	1.0	21
70	Total pancreatectomy: how, when and why?. <i>Updates in Surgery</i> , 2021, 73, 1203-1204.	0.9	3
71	Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis. <i>Pancreatology</i> , 2021, 21, 1395-1401.	0.5	20
72	Total pancreatectomy sequelae and quality of life: results of islet autotransplantation as a possible mitigation strategy. <i>Updates in Surgery</i> , 2021, 73, 1237-1246.	0.9	9

#	ARTICLE	IF	CITATIONS
73	Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. <i>Annals of Surgical Oncology</i> , 2021, 28, 8249-8260.	0.7	20
74	A tug-of-war in intraductal papillary mucinous neoplasms management: Comparison between 2017 International and 2018 European guidelines. <i>Digestive and Liver Disease</i> , 2021, 53, 998-1003.	0.4	12
75	Utility of the 2019 ACR/EULAR classification criteria for the management of patients with IgG4-related disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 761-765.	1.6	6
76	The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. <i>Annals of Surgery</i> , 2021, 274, 721-728.	2.1	24
77	Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma?. <i>Digestive and Liver Disease</i> , 2021, 53, 1065-1067.	0.4	0
78	Resectability of Pancreatic Cancer Is in the Eye of the Observer. <i>Annals of Surgery Open</i> , 2021, 2, e087.	0.7	8
79	Evaluation of cost-effectiveness among open, laparoscopic and robotic distal pancreatectomy: A systematic review and meta-analysis. <i>American Journal of Surgery</i> , 2021, 222, 513-520.	0.9	16
80	Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 608.	0.7	22
81	Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. <i>Cancers</i> , 2021, 13, 4938.	1.7	16
82	Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomized Controlled Trial. <i>Cancers</i> , 2021, 13, 4512.	1.7	7
83	The role of acinar content at pancreatic resection margin in the development of postoperative pancreatic fistula and acute pancreatitis after pancreaticoduodenectomy. <i>Surgery</i> , 2021, 170, 1215-1222.	1.0	15
84	The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis. <i>Surgery</i> , 2021, 170, 1195-1204.	1.0	11
85	Non Functional Pancreatic Neuroendocrine Tumors. , 2021, , 125-135.		0
86	Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: Possible clinical impact of misclassification. <i>Endoscopic Ultrasound</i> , 2021, 10, 372.	0.6	11
87	EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). <i>Cancers</i> , 2021, 13, 5014.	1.7	9
88	Evaluation of factors predicting loss of benefit provided by laparoscopic distal pancreatectomy compared to open approach. <i>Updates in Surgery</i> , 2021, , 1.	0.9	2
89	Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies. <i>Frontiers in Oncology</i> , 2021, 11, 812102.	1.3	3
90	Development of a conceptual framework of recovery after abdominal surgery. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 2665-2674.	1.3	18

#	ARTICLE	IF	CITATIONS
91	B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 968-981.e14.	1.5	85
92	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. <i>Annals of Surgical Oncology</i> , 2020, 27, 1348-1355.	0.7	44
93	Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals. <i>International Journal of Cancer</i> , 2020, 146, 1316-1323.	2.3	19
94	Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. <i>European Journal of Internal Medicine</i> , 2020, 74, 92-98.	1.0	52
95	Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 1986-1996.	0.7	31
96	Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer": What Is Good for the Surgeon Is Just as Good for the Patient?. <i>Annals of Surgery</i> , 2020, 271, e106-e107.	2.1	1
97	Islet autotransplantation: Indication beyond chronic pancreatitis. , 2020, , 127-137.		0
98	Review of the diagnosis and management of intraductal papillary mucinous neoplasms. <i>United European Gastroenterology Journal</i> , 2020, 8, 249-255.	1.6	18
99	Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. <i>Annals of Surgery</i> , 2020, 272, 731-737.	2.1	49
100	Italian registry of families at risk of pancreatic cancer: AISP Familial Pancreatic Cancer Study Group. <i>Digestive and Liver Disease</i> , 2020, 52, 1126-1130.	0.4	10
101	Implications of increased serum amylase after pancreaticoduodenectomy: toward a better definition of clinically relevant postoperative acute pancreatitis. <i>Hpb</i> , 2020, 22, 1645-1653.	0.1	33
102	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. <i>Surgical Oncology</i> , 2020, 35, 141-148.	0.8	14
103	Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2317-2324.	0.9	0
104	Robustness of CT radiomic features against image discretization and interpolation in characterizing pancreatic neuroendocrine neoplasms. <i>Physica Medica</i> , 2020, 76, 125-133.	0.4	21
105	RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features. <i>Cells</i> , 2020, 9, 2561.	1.8	11
106	Preoperative predictive factors of laparoscopic distal pancreatectomy difficulty. <i>Hpb</i> , 2020, 22, 1766-1774.	0.1	13
107	Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors. <i>Surgery</i> , 2020, 168, 816-824.	1.0	4
108	Dual tracer ⁶⁸ Ga-DOTATOC and ¹⁸ F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. <i>Nuclear Medicine Communications</i> , 2020, 41, 896-905.	0.5	28

#	ARTICLE	IF	CITATIONS
109	Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. <i>JAMA Oncology</i> , 2020, 6, 1733.	3.4	85
110	B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. <i>Oncolimmunology</i> , 2020, 9, 1794359.	2.1	25
111	Factors Associated With the Risk of Progression of Low-Risk Branch-Duct Intraductal Papillary Mucinous Neoplasms. <i>JAMA Network Open</i> , 2020, 3, e2022933.	2.8	25
112	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , 2020, 7, 598438.	1.2	33
113	Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT). <i>Endocrine Pathology</i> , 2020, 31, 119-131.	5.2	13
114	A Preoperative Clinical Risk Score Including C-Reactive Protein Predicts Histological Tumor Characteristics and Patient Survival after Surgery for Sporadic Non-Functional Pancreatic Neuroendocrine Neoplasms: An International Multicenter Cohort Study. <i>Cancers</i> , 2020, 12, 1235.	1.7	12
115	Pancreatic metastasis of papillary thyroid carcinoma with an intraductal growth pattern. <i>Endoscopy</i> , 2020, 52, E452-E453.	1.0	2
116	Perspectives from Italy during the COVID-19 pandemic: nationwide survey-based focus on minimally invasive HPB surgery. <i>Updates in Surgery</i> , 2020, 72, 241-247.	0.9	19
117	The Italian National Registry for minimally invasive pancreatic surgery: an initiative of the Italian Group of Minimally Invasive Pancreas Surgery (IGoMIPS). <i>Updates in Surgery</i> , 2020, 72, 379-385.	0.9	1
118	ASO Author Reflections: Circulating Neuroendocrine Gene Transcripts (NETest): A Promising Biomarker for Pancreatic Neuroendocrine Tumours (PanNET). <i>Annals of Surgical Oncology</i> , 2020, 27, 3937-3938.	0.7	2
119	Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 641-650.	1.1	8
120	Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. <i>Rheumatology</i> , 2020, 59, 2435-2442.	0.9	46
121	The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492093660.	0.6	5
122	A systematic review and meta-analysis on the role of omental or falciform ligament wrapping during pancreaticoduodenectomy. <i>Hpb</i> , 2020, 22, 1227-1239.	0.1	26
123	The Applicability of a Checklist for the Diagnosis and Treatment of Exocrine Pancreatic Insufficiency. <i>Pancreas</i> , 2020, 49, 793-798.	0.5	3
124	Pancreatic fistula after pancreaticoduodenectomy—does surgical technique matter?. <i>Annals of Translational Medicine</i> , 2020, 8, 669-669.	0.7	3
125	Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatoduodenectomy for pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1524-1531.	0.5	14
126	Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. <i>Digestive and Liver Disease</i> , 2020, 52, 392-399.	0.4	28

#	ARTICLE	IF	CITATIONS
127	Epidemiology, clinical features and diagnostic work-up of cystic neoplasms of the pancreas: Interim analysis of the prospective PANCY survey. <i>Digestive and Liver Disease</i> , 2020, 52, 547-554.	0.4	21
128	Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 275.	1.7	50
129	Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms. <i>Current Treatment Options in Oncology</i> , 2020, 21, 48.	1.3	13
130	Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3. <i>American Journal of Surgery</i> , 2020, 220, 284-289.	0.9	19
131	Standards for reporting on surgery for chronic pancreatitis: a report from the International Study Group for Pancreatic Surgery (ISGPS). <i>Surgery</i> , 2020, 168, 101-105.	1.0	9
132	Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). <i>Surgery</i> , 2020, 168, 72-84.	1.0	48
133	Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2020, 27, 3928-3936.	0.7	19
134	A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. <i>Updates in Surgery</i> , 2020, 72, 39-45.	0.9	17
135	Main Duct Thresholds for Malignancy Are Different in Intraductal Papillary Mucinous Neoplasms of the Pancreatic Head and Body-Tail. <i>Clinical Gastroenterology and Hepatology</i> , 2020, , .	2.4	11
136	Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer. <i>Endoscopy International Open</i> , 2020, 08, E1511-E1519.	0.9	6
137	Disease-free survival as a measure of overall survival in resected pancreatic endocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2020, 27, 275-283.	1.6	6
138	Application of minimally invasive pancreatic surgery: an Italian survey. <i>Updates in Surgery</i> , 2019, 71, 97-103.	0.9	7
139	Prognostic role of hyponatremia in pancreatic cancer. <i>Annals of Oncology</i> , 2019, 30, iv7.	0.6	0
140	A multimodality test to guide the management of patients with a pancreatic cyst. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	129
141	Nerves and Pancreatic Cancer: New Insights into a Dangerous Relationship. <i>Cancers</i> , 2019, 11, 893.	1.7	50
142	Long-Term Pancreatic Functional Impairment after Surgery for Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2019, 8, 1611.	1.0	11
143	P.03.15 APPLICABILITY OF A CHECKLIST FOR THE DIAGNOSIS AND TREATMENT OF SEVERE EXOCRINE PANCREATIC INSUFFICIENCY (EPI). PRELIMINARY RESULTS OF AN EPI ITALIAN REGISTRY (EPITALY). <i>Digestive and Liver Disease</i> , 2019, 51, e170.	0.4	1
144	⁶⁸ Ga-DOTA-peptides PET/MRI in pancreatico-duodenal neuroendocrine tumours: a flash pictorial essay on assets and lacks. <i>Clinical and Translational Imaging</i> , 2019, 7, 363-371.	1.1	4

#	ARTICLE	IF	CITATIONS
145	Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. <i>Cancer Treatment Reviews</i> , 2019, 77, 1-10.	3.4	48
146	Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). <i>Clinical and Translational Imaging</i> , 2019, 7, 181-188.	1.1	18
147	Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. <i>BMC Cancer</i> , 2019, 19, 569.	1.1	11
148	Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life. <i>Surgery</i> , 2019, 166, 157-163.	1.0	40
149	Is the Real Prevalence of Pancreatic Neuroendocrine Tumors Underestimated? A Retrospective Study on a Large Series of Pancreatic Specimens. <i>Neuroendocrinology</i> , 2019, 109, 165-170.	1.2	26
150	Diagnostic strategy with a solid pancreatic mass. <i>Presse Medicale</i> , 2019, 48, e125-e145.	0.8	15
151	Duodeno-jejunal or gastro-enteric leakage after pancreatic resection: a case-control study. <i>Updates in Surgery</i> , 2019, 71, 295-303.	0.9	3
152	The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age. <i>Digestive and Liver Disease</i> , 2019, 51, 735-740.	0.4	15
153	The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer. , 2019, 7, 45.		54
154	Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study. <i>Frontiers in Oncology</i> , 2019, 9, 1299.	1.3	12
155	Risk and Predictors of Postoperative Morbidity and Mortality After Pancreaticoduodenectomy for Pancreatic Neuroendocrine Neoplasms. <i>Pancreas</i> , 2019, 48, 504-509.	0.5	26
156	Methotrexate as Induction of Remission Therapy for Type 1 Autoimmune Pancreatitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 831-833.	0.2	13
157	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2019, 270, 422-433.	2.1	53
158	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2019, 9, 18614.	1.6	26
159	Neuroendocrine Tumors (NETs) of the Minor Papilla/Ampulla. <i>American Journal of Surgical Pathology</i> , 2019, 43, 725-736.	2.1	18
160	Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). <i>Pancreatology</i> , 2019, 19, 57-63.	0.5	6
161	Systematic review and meta-analysis: Prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals. <i>Pancreatology</i> , 2019, 19, 2-9.	0.5	136
162	Ct radiomic features of pancreatic neuroendocrine neoplasms (panNEN) are robust against delineation uncertainty. <i>Physica Medica</i> , 2019, 57, 41-46.	0.4	22

#	ARTICLE	IF	CITATIONS
163	Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry. <i>American Journal of Gastroenterology</i> , 2019, 114, 665-670.	0.2	35
164	Diabetes-free survival after extended distal pancreatectomy and islet auto transplantation for benign or borderline/malignant lesions of the pancreas. <i>American Journal of Transplantation</i> , 2019, 19, 920-928.	2.6	11
165	Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. <i>Translational Oncology</i> , 2019, 12, 1-7.	1.7	18
166	Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2019, 108, 26-36.	1.2	46
167	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. <i>European Journal of Surgical Oncology</i> , 2019, 45, 46-51.	0.5	3
168	The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs). <i>Annals of Surgery</i> , 2019, 269, 725-732.	2.1	50
169	Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA). <i>Annals of Surgery</i> , 2019, 269, 10-17.	2.1	211
170	Local treatment for focal progression in metastatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, 405-409.	1.6	10
171	New era for pancreatic endoscopic ultrasound: From imaging to molecular pathology of pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 933-945.	0.8	8
172	Which is the best pancreatic anastomosis?. <i>Minerva Chirurgica</i> , 2019, 74, 241-252.	0.8	2
173	Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 159-166.	0.4	13
174	A $CD4^{hi}$ Subset of $CD4^{+}SLAMF7^{+}$ Cytotoxic T Cells Is Expanded in Patients With IgG4-Related Disease and Decreases Following Glucocorticoid Treatment. <i>Arthritis and Rheumatology</i> , 2018, 70, 1133-1143.	2.9	87
175	Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2/3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 413-423.	3.7	180
176	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , 2018, 18, 198-203.	0.5	18
177	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	6.0	1,872
178	Meta-analysis of mortality in patients with high-risk intraductal papillary mucinous neoplasms under observation. <i>British Journal of Surgery</i> , 2018, 105, 328-338.	0.1	41
179	A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. <i>Hpb</i> , 2018, 20, 197-203.	0.1	29
180	Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. <i>Surgery</i> , 2018, 163, 761-767.	1.0	65

#	ARTICLE	IF	CITATIONS
181	Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. <i>World Journal of Surgery</i> , 2018, 42, 3223-3230.	0.8	29
182	European evidence-based guidelines on pancreatic cystic neoplasms. <i>Gut</i> , 2018, 67, 789-804.	6.1	878
183	The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. <i>European Journal of Surgical Oncology</i> , 2018, 44, 778-783.	0.5	49
184	How should incidental NEN of the pancreas and gastrointestinal tract be followed?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 139-144.	2.6	7
185	A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2018, 267, 1148-1154.	2.1	101
186	Role of Minimally Invasive Surgery in the Treatment of Pancreatic Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018, , 141-147.	0.0	1
187	Minimally Invasive Pancreatectomy plus Islet Autotransplantation for Benign Tumors of the Pancreatic Neck and Body. <i>Updates in Surgery Series</i> , 2018, , 187-194.	0.0	0
188	SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer. <i>Digestive and Liver Disease</i> , 2018, 50, 84-90.	0.4	10
189	Prognosis of sporadic resected small (≤2cm) nonfunctional pancreatic neuroendocrine tumors – a multi-institutional study. <i>Hpb</i> , 2018, 20, 251-259.	0.1	99
190	Endovascular Repair of 40 Visceral Artery Aneurysms and Pseudoaneurysms with the Viabahn Stent-Graft: Technical Aspects, Clinical Outcome and Mid-Term Patency. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 385-397.	0.9	58
191	Pancreatic enzyme replacement therapy after gastric resection: An update. <i>Digestive and Liver Disease</i> , 2018, 50, 1-5.	0.4	15
192	Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 24-30.	0.5	24
193	Clinical Usefulness of 18 F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms. <i>Oncologist</i> , 2018, 23, 186-192.	1.9	39
194	Allo- and auto-percutaneous intra-portal pancreatic islet transplantation (PIPIT) for diabetes cure and prevention: the role of imaging and interventional radiology. <i>Gland Surgery</i> , 2018, 7, 117-131.	0.5	12
195	Unmet needs in the management of neuroendocrine tumours (NETs): A global survey of patients, patient advocates and healthcare professionals. <i>Annals of Oncology</i> , 2018, 29, viii475-viii476.	0.6	0
196	Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse. <i>Arthritis Research and Therapy</i> , 2018, 20, 222.	1.6	41
197	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. <i>Neuroendocrinology</i> , 2018, 107, 375-386.	1.2	78
198	Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with clinical outcome. <i>Pancreatology</i> , 2018, 18, 945-953.	0.5	8

#	ARTICLE	IF	CITATIONS
199	Endoscopic ultrasound appearance of pancreatic serotonin-staining neuroendocrine neoplasms. <i>Pancreatology</i> , 2018, 18, 792-798.	0.5	7
200	Focus on pancreatic cancer. <i>Digestive and Liver Disease</i> , 2018, 50, 1272-1273.	0.4	0
201	Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67. <i>Annals of Surgical Oncology</i> , 2018, 25, 2467-2474.	0.7	82
202	No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. <i>Cancer Biomarkers</i> , 2018, 22, 351-357.	0.8	1
203	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. <i>Annals of Surgical Oncology</i> , 2018, 25, 3200-3206.	0.7	39
204	Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2018, 13, e0197035.	1.1	20
205	Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 691-697.	3.7	50
206	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 102, 95-102.	1.3	50
207	Surveillance of Cystic Lesions of the Pancreas: Whom and How to Survey?. <i>Visceral Medicine</i> , 2018, 34, 202-205.	0.5	6
208	Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 european patientsâ€”The ENETS registry.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4095-4095.	0.8	4
209	Pancreatic cystic neoplasms: What is the most cost-effective follow-up strategy?. <i>Endoscopic Ultrasound</i> , 2018, 7, 319.	0.6	8
210	Therapy for Locoregional Disease: Pancreas. , 2018, , 235-254.		0
211	Pancreatic Neuroendocrine Tumours. , 2018, , 333-343.		0
212	Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis. <i>Gut</i> , 2017, 66, 495-506.	6.1	177
213	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2017, 105, 255-265.	1.2	231
214	Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. <i>Oncologist</i> , 2017, 22, 409-415.	1.9	42
215	Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management. <i>American Journal of Gastroenterology</i> , 2017, 112, 1153-1161.	0.2	66
216	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 152-165.	2.0	28

#	ARTICLE	IF	CITATIONS
217	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2017, 105, 245-254.	1.2	122
218	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017, 543, 65-71.	13.7	716
219	Early Postoperative Prediction of Clinically Relevant Pancreatic Fistula after Pancreaticoduodenectomy: usefulness of C-reactive Protein. <i>Hpb</i> , 2017, 19, 580-586.	0.1	52
220	Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1486-1494.	1.8	27
221	Guideline for the Management of Pancreatic Neuroendocrine Tumor. , 2017, , 161-172.		0
222	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017, 6, 1493-1499.	1.3	11
223	Salvage Islet Auto Transplantation After Relaparatomy. <i>Transplantation</i> , 2017, 101, 2492-2500.	0.5	6
224	Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2017, 266, e108-e109.	2.1	4
225	Defining rules for increasingly personalized treatments. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 80-82.	12.5	6
226	The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. <i>Surgery</i> , 2017, 161, 584-591.	1.0	2,655
227	Human White Adipocytes Convert Into “Rainbow” Adipocytes In Vitro. <i>Journal of Cellular Physiology</i> , 2017, 232, 2887-2899.	2.0	28
228	Borderline resectable pancreatic cancer: More than an anatomical concept. <i>Digestive and Liver Disease</i> , 2017, 49, 223-226.	0.4	15
229	miR-204 is associated with an endocrine phenotype in human pancreatic islets but does not regulate the insulin mRNA through MAFA. <i>Scientific Reports</i> , 2017, 7, 14051.	1.6	11
230	Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2017, 28, 2786-2792.	0.6	87
231	Diagnosis and treatment in chronic pancreatitis: an international survey and case vignette study. <i>Hpb</i> , 2017, 19, 978-985.	0.1	22
232	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207.	3.3	438
233	Response to Malleo et al.. <i>American Journal of Gastroenterology</i> , 2017, 112, 1481-1482.	0.2	0
234	A preoperative score to predict early death after pancreatic cancer resection. <i>Digestive and Liver Disease</i> , 2017, 49, 1050-1056.	0.4	28

#	ARTICLE	IF	CITATIONS
235	Results of Non-Operative Management for Intraductal Papillary Mucinous Neoplasms with High-Risk Stigmata or Worrisome Features: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2017, 152, S681-S682.	0.6	0
236	Surveillance for Pancreatic Cancer in High-Risk Individuals: First-Round Screening Results of a Multicentric Italian Program. <i>Gastroenterology</i> , 2017, 152, S1291.	0.6	1
237	Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. <i>Rheumatology</i> , 2017, 56, 2084-2092.	0.9	60
238	Endovascular Treatment of Visceral Artery Aneurysms and Pseudoaneurysms in 100 Patients: Covered Stenting vs Transcatheter Embolization. <i>Journal of Endovascular Therapy</i> , 2017, 24, 709-717.	0.8	41
239	Systematic review and meta-analysis on laparoscopic pancreatic resections for neuroendocrine neoplasms (PNETs). <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 65-73.	1.4	32
240	Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. <i>European Journal of Surgical Oncology</i> , 2017, 43, 372-379.	0.5	46
241	Somatostatin analogs: is one better than other?. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 817-819.	1.4	2
242	Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2017, 18, 419-449.	0.6	4
243	Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 301-310.	1.8	12
244	Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2017, 12, e0179445.	1.1	45
245	Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 301-310.	1.8	10
246	Zalecenia dotyczące postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynych układu pokarmowego (rekomendowane przez Polską Sieć Guzów) <i>Tj ETQq0 0 0 rgBT / Overlock 1046 50 297</i>		
247	Nowotwory neuroendokryne i dwunastnicy z uwzględnieniem gastrinoma (zasady postępowania) <i>Tj ETQq1 1 0 7843 14</i>	0.3	20
248	Nowotwory neuroendokryne jelita cienkiego i wyrostka robaczkowego – zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynych). <i>Endokrynologia Polska</i> , 2017, 68, 223-236.	0.3	18
249	Nowotwory neuroendokryne jelita grubego – zasady postępowania (rekomendowane przez Polską Sieć Guzów) <i>Tj ETQq1 1 0 7843 14</i>	0.3	20
250	Pancreatic ductal adenocarcinoma in 2017: Time to change the therapeutic algorithm?. <i>Endoscopic Ultrasound</i> , 2017, 6, 62.	0.6	1
251	Abstract 3519: TGF-β2 pathway alteration in pancreatic neuroendocrine tumors: characterization of a novel SMAD3 translocation. , 2017, , .		0
252	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs). <i>Annals of Oncology</i> , 2016, 27, vi145.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study. PLoS ONE, 2016, 11, e0166008.	1.1	20
254	Reassessment of proliferative activity at disease progression in neuroendocrine neoplasms. Annals of Oncology, 2016, 27, vi143.	0.6	0
255	Systematic review and meta-analysis of metal versus plastic stents for preoperative biliary drainage in resectable periampullary or pancreatic head tumors. European Journal of Surgical Oncology, 2016, 42, 1278-1285.	0.5	67
256	Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?. European Journal of Surgical Oncology, 2016, 42, 1533-1539.	0.5	104
257	Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. Annals of Surgery, 2016, 264, 949-958.	2.1	95
258	Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review and meta-analysis. Digestive and Liver Disease, 2016, 48, 473-479.	0.4	78
259	Justifying vein resection with pancreatoduodenectomy. Lancet Oncology, The, 2016, 17, e177-e178.	5.1	3
260	597 Molecular Markers Help Define Cyst Type in the Pancreas: An International, Multicenter Study of Over 300 Cysts. Gastroenterology, 2016, 150, S121.	0.6	0
261	Sa1389 Clinical Usefulness of Functional Imaging Tests in the Follow-Up of Digestive Neuroendocrine Neoplasms. Gastroenterology, 2016, 150, S302.	0.6	0
262	Active Surveillance versus Surgery of Nonfunctioning Pancreatic Neuroendocrine Neoplasms ≥2 cm in MEN1 Patients. Neuroendocrinology, 2016, 103, 779-786.	1.2	49
263	Comment traiter le moignon pancréatique après duodénopancréatectomie œphalique. Journal De Chirurgie Viscérale, 2016, 153, 199-209.	0.0	0
264	Surgical management of the pancreatic stump following pancreato-duodenectomy. Journal of Visceral Surgery, 2016, 153, 193-202.	0.4	14
265	Diabetes associated with pancreatic ductal adenocarcinoma is just diabetes: Results of a prospective observational study in surgical patients. Pancreatology, 2016, 16, 844-852.	0.5	13
266	Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1â€G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. Annals of Surgical Oncology, 2016, 23, 981-989.	0.7	58
267	mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2016, 23, 883-891.	1.6	28
268	Systematic review of active surveillance <i>versus</i> surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. British Journal of Surgery, 2016, 104, 34-41.	0.1	140
269	Treatment of branch-duct intraductal papillary mucinous neoplasms of the pancreas: state of the art. Updates in Surgery, 2016, 68, 265-271.	0.9	8
270	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocrine Connections, 2016, 5, 174-187.	0.8	83

#	ARTICLE	IF	CITATIONS
271	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. <i>Neuroendocrinology</i> , 2016, 103, 531-537.	1.2	28
272	Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2016, 115, 290-296.	2.9	29
273	Congenital bile duct cyst (BDC) is a more indolent disease in children compared to adults, except for Todani type IV-A BDC: results of the European multicenter study of the French Surgical Association. <i>Hpb</i> , 2016, 18, 529-539.	0.1	11
274	Insulin resistance is associated with the aggressiveness of pancreatic ductal carcinoma. <i>Acta Diabetologica</i> , 2016, 53, 945-956.	1.2	21
275	Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2016, 27, vi230.	0.6	2
276	Autologous Islet Transplantation in Patients Requiring Pancreatectomy: A Broader Spectrum of Indications Beyond Chronic Pancreatitis. <i>American Journal of Transplantation</i> , 2016, 16, 1812-1826.	2.6	46
277	Single-centre experience of extending indications for percutaneous intraportal islet autotransplantation (PIPIAT) after pancreatic surgery to prevent diabetes: feasibility, radiological aspects, complications and clinical outcome. <i>British Journal of Radiology</i> , 2016, 89, 20160246.	1.0	7
278	Pancreaticojejunostomy is comparable to pancreaticogastrostomy after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. <i>Langenbeck's Archives of Surgery</i> , 2016, 401, 427-437.	0.8	49
279	Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group) <i>Tj ETQq1 1 0 784314 29 BT /Ov</i>		
280	Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review. <i>Advances in Medical Sciences</i> , 2016, 61, 147-153.	0.9	45
281	Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategyâ€”A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 264-274.	2.0	26
282	A systematic review and meta-analysis of spleen-preserving distal pancreatectomy with preservation or ligation of the splenic artery and vein. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2016, 14, 109-118.	0.8	28
283	Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients. <i>Cancer Research</i> , 2016, 76, 1792-1803.	0.4	114
284	Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. <i>Surgery</i> , 2016, 159, 862-871.	1.0	65
285	ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2016, 103, 153-171.	1.2	1,074
286	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 309-324.	2.0	35
287	Evaluation of an enhanced recovery protocol after pancreaticoduodenectomy in elderly patients. <i>Hpb</i> , 2016, 18, 153-158.	0.1	43
288	Risk of misdiagnosis and overtreatment in patients with main pancreatic duct dilatation and suspected combined/main-duct intraductal papillary mucinous neoplasms. <i>Surgery</i> , 2016, 159, 1041-1049.	1.0	51

#	ARTICLE	IF	CITATIONS
289	Intraductal papillary mucinous neoplasms of the pancreas with concurrent pancreatic and periampullary neoplasms. <i>European Journal of Surgical Oncology</i> , 2016, 42, 197-204.	0.5	35
290	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. <i>Pancreatology</i> , 2016, 16, 14-27.	0.5	81
291	Surgical management of neuroendocrine tumors. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 93-102.	2.2	27
292	(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. <i>Clinical Cancer Research</i> , 2016, 22, 1076-1085.	3.2	146
293	Single-incision laparoscopic cholecystectomy versus traditional laparoscopic cholecystectomy performed by a single surgeon: findings of a randomized trial. <i>Surgery Today</i> , 2016, 46, 313-318.	0.7	19
294	Enhanced recovery pathways in pancreatic surgery: State of the art. <i>World Journal of Gastroenterology</i> , 2016, 22, 6456.	1.4	49
295	Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. <i>World Journal of Gastroenterology</i> , 2016, 22, 9944.	1.4	30
296	Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 389.	0.8	20
297	Functional imaging tests and CT scan: Detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up.. <i>Journal of Clinical Oncology</i> , 2016, 34, 219-219.	0.8	0
298	Nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15654-e15654.	0.8	0
299	Abstract 3401: Impact of VEGF and VEGFR polymorphisms on neuroendocrine tumors of the gastro-entero-pancreatic system (GEPNETs) outcome. , 2016, , .		0
300	Todani Type II Congenital Bile Duct Cyst. <i>Annals of Surgery</i> , 2015, 262, 130-138.	2.1	29
301	Management of ampullary neoplasms: A tailored approach between endoscopy and surgery. <i>World Journal of Gastroenterology</i> , 2015, 21, 7970.	1.4	59
302	<i>Lgr5</i> expression, cancer stem cells and pancreatic cancer: results from biological and computational analyses. <i>Future Oncology</i> , 2015, 11, 1037-1045.	1.1	10
303	Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases. <i>Neuroendocrinology</i> , 2015, 102, 68-76.	1.2	71
304	Pancreatic Surgery. <i>Frontiers of Hormone Research</i> , 2015, 44, 139-148.	1.0	7
305	Glial-Like Differentiation Potential of Human Mature Adipocytes. <i>Journal of Molecular Neuroscience</i> , 2015, 55, 91-98.	1.1	13
306	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. <i>Annals of Oncology</i> , 2015, 26, 1604-1620.	0.6	514

#	ARTICLE	IF	CITATIONS
307	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.	13.7	2,132
308	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	0.7	72
309	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. <i>Gastroenterology</i> , 2015, 149, 1501-1510.	0.6	376
310	Quality assessment of the guidelines on cystic neoplasms of the pancreas. <i>Pancreatology</i> , 2015, 15, 463-469.	0.5	19
311	Biosafety evidence for human dedifferentiated adipocytes. <i>Journal of Cellular Physiology</i> , 2015, 230, 1525-1533.	2.0	10
312	Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making. <i>International Journal of Surgery</i> , 2015, 20, 58-64.	1.1	20
313	Interaction between human mature adipocytes and lymphocytes induces T-cell proliferation. <i>Cytotherapy</i> , 2015, 17, 1292-1301.	0.3	20
314	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.2	58
315	Abstract 3455: Functional imaging tests vs. computed tomography scan: detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up. , 2015, , .		0
316	Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (≥75 years) Patients. <i>Anticancer Research</i> , 2015, 35, 3441-6.	0.5	5
317	A multicenter survey on distal pancreatectomy in Italy: results of minimally invasive technique and variability of perioperative pathways. <i>Updates in Surgery</i> , 2014, 66, 253-263.	0.9	22
318	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. <i>Oncologist</i> , 2014, 19, 966-974.	1.9	84
319	GEPNETS UPDATE: A review on surgery of gastro-entero-pancreatic neuroendocrine tumors. <i>European Journal of Endocrinology</i> , 2014, 171, R153-R162.	1.9	30
320	Long-Term Outcome after Laparoscopic Bowel Resections for Deep Infiltrating Endometriosis: A Single-Center Experience after 900 Cases. <i>BioMed Research International</i> , 2014, 2014, 1-5.	0.9	39
321	Extent of Surgery and Implications of Transection Margin Status after Resection of IPMNs. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-10.	0.7	18
322	Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. <i>International Journal of Cancer</i> , 2014, 135, 1110-1118.	2.3	192
323	Advanced Digestive Neuroendocrine Tumors. <i>Pancreas</i> , 2014, 43, 212-218.	0.5	46
324	Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. <i>Digestive and Liver Disease</i> , 2014, 46, 479-493.	0.4	108

#	ARTICLE	IF	CITATIONS
325	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 321-331.	2.7	27
326	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 176-177.	3.3	1
327	Management of rectosigmoid obstruction due to severe bowel endometriosis. <i>Updates in Surgery</i> , 2014, 66, 59-64.	0.9	12
328	Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors. <i>Langenbeck's Archives of Surgery</i> , 2014, 399, 315-321.	0.8	78
329	Comment on "Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine". <i>Surgery</i> , 2014, 155, 582-584.	1.0	1
330	Evaluation of a predictive model for pancreatic fistula based on amylase value in drains after pancreatic resection. <i>American Journal of Surgery</i> , 2014, 208, 634-639.	0.9	41
331	Multi-institutional Pooled Analysis on Adjuvant Chemoradiation in Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 911-917.	0.4	55
332	The role of 18fluoro-deoxyglucose positron emission tomography/computed tomography in resectable pancreatic cancer. <i>Digestive and Liver Disease</i> , 2014, 46, 744-749.	0.4	14
333	Different reconstruction techniques after pancreatoduodenectomy do not affect clinical and patient reported outcomes. <i>Advances in Medical Sciences</i> , 2014, 59, 151-155.	0.9	6
334	Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. <i>Surgery</i> , 2014, 155, 145-153.	1.0	92
335	Right hemicolectomy plus pancreaticoduodenectomy vs partial duodenectomy in treatment of locally advanced right colon cancer invading pancreas and/or only duodenum. <i>Surgical Oncology</i> , 2014, 23, 92-98.	0.8	31
336	Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: Possible indications for a multimodal approach. <i>Surgery</i> , 2014, 155, 607-614.	1.0	71
337	The natural history of a branch-duct intraductal papillary mucinous neoplasm of the pancreas. <i>Surgery</i> , 2014, 155, 578-579.	1.0	9
338	Selection criteria in resectable pancreatic cancer: A biological and morphological approach. <i>World Journal of Gastroenterology</i> , 2014, 20, 11210.	1.4	31
339	Questions About Branch-Duct IPMNs With Sendai Negative Criteria. <i>Annals of Surgery</i> , 2014, 259, e42.	2.1	0
340	The Role of Combined 68Ga-DOTANOC and 18FDG PET/CT in the Management of Patients with Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2014, 100, 293-299.	1.2	51
341	Molecular Targeted Therapy in Enteropancreatic Neuroendocrine Tumors: From Biology to Clinical Practice. <i>Current Medicinal Chemistry</i> , 2014, 21, 1017-1025.	1.2	10
342	Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas. <i>World Journal of Gastroenterology</i> , 2014, 20, 10008.	1.4	21

#	ARTICLE	IF	CITATIONS
343	Surgical management of pancreatic neuroendocrine neoplasms. <i>Annals of Saudi Medicine</i> , 2014, 34, 1-5.	0.5	7
344	Spectrum of magnetic resonance imaging findings in pancreatic and other abdominal manifestations of Von Hippel-Lindau disease in a series of 23 patients: a pictorial review. <i>JOP: Journal of the Pancreas</i> , 2014, 15, 1-18.	1.5	9
345	Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?. <i>Journal of Clinical Oncology</i> , 2014, 32, e15563-e15563.	0.8	0
346	Adequacy of Lymph Node Retrieval for Ampullary Cancer and Its Association with Improved Staging and Survival. <i>World Journal of Surgery</i> , 2013, 37, 1397-1404.	0.8	25
347	Preoperative assessment of nonfunctioning pancreatic endocrine tumours: role of MDCT and MRI. <i>Radiologia Medica</i> , 2013, 118, 1082-1101.	4.7	21
348	Re: "Long-term comparison of laparoscopy-assisted distal gastrectomy and open distal gastrectomy in advanced gastric cancer" (<i>Surg Endosc</i> (2010) 24:1:63-67). <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 3050-3051.	1.3	0
349	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1197-1205.	3.3	50
350	A systematic review on robotic pancreaticoduodenectomy. <i>Surgical Oncology</i> , 2013, 22, 238-246.	0.8	76
351	Current status of robotic distal pancreatectomy: A systematic review. <i>Surgical Oncology</i> , 2013, 22, 201-207.	0.8	51
352	European experts consensus statement on cystic tumours of the pancreas. <i>Digestive and Liver Disease</i> , 2013, 45, 703-711.	0.4	406
353	Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. <i>Journal of Clinical Oncology</i> , 2013, 31, 1348-1356.	0.8	142
354	Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. <i>Hpb</i> , 2013, 15, 935-943.	0.1	16
355	Outcomes of intraductal papillary mucinous neoplasm with "Sendai-positive" criteria for resection undergoing non-operative management. <i>Digestive and Liver Disease</i> , 2013, 45, 584-588.	0.4	22
356	Perfusion CT can predict tumoral grading of pancreatic adenocarcinoma. <i>European Journal of Radiology</i> , 2013, 82, 227-233.	1.2	44
357	Minimally Invasive Necrosectomy Versus Conventional Surgery in the Treatment of Infected Pancreatic Necrosis. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2013, 23, 8-20.	0.4	45
358	Pattern and Clinical Predictors of Lymph Node Involvement in Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNETs). <i>JAMA Surgery</i> , 2013, 148, 932.	2.2	154
359	Observational Study of Natural History of Small Sporadic Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4784-4789.	1.8	212
360	Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre. <i>Hpb</i> , 2013, 15, 958-964.	0.1	16

#	ARTICLE	IF	CITATIONS
361	Partial Pancreaticoduodenectomy Can Provide Cure for Duodenal Gastrinoma Associated With Multiple Endocrine Neoplasia Type 1. <i>Annals of Surgery</i> , 2013, 257, 308-314.	2.1	84
362	Exocrine pancreatic insufficiency in adults: A shared position statement of the Italian association for the study of the pancreas. <i>World Journal of Gastroenterology</i> , 2013, 19, 7930.	1.4	98
363	Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study. <i>PLoS ONE</i> , 2013, 8, e54824.	1.1	44
364	Presentation, diagnostic features and glucose handling in a monocentric series of insulinomas. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 753-8.	1.8	12
365	Surgical Therapy. <i>Updates in Surgery Series</i> , 2013, , 109-116.	0.0	0
366	Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. <i>Annals of Oncology</i> , 2012, 23, 127-134.	0.6	56
367	Rectal Indomethacin to Prevent Post-ERCP Pancreatitis. <i>New England Journal of Medicine</i> , 2012, 367, 277-279.	13.9	14
368	Surgical Management of Insulinomas. <i>Archives of Surgery</i> , 2012, 147, 261.	2.3	126
369	TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study. <i>Journal of the National Cancer Institute</i> , 2012, 104, 764-777.	3.0	420
370	Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. <i>Annals of Oncology</i> , 2012, 23, 1928.	0.6	9
371	International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. <i>Pancreatology</i> , 2012, 12, 183-197.	0.5	2,043
372	Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2012, 96, 32-40.	1.2	55
373	Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. <i>American Journal of Surgery</i> , 2012, 203, 132-139.	0.9	86
374	Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resections. <i>European Journal of Cancer</i> , 2012, 48, 1608-1615.	1.3	149
375	Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. <i>British Journal of Surgery</i> , 2012, 99, 1480-1486.	0.1	128
376	Intraductal papillary mucinous neoplasms of the biliary and pancreatic ductsâ€”A shape shifting outlook into an increasingly recognized disease. <i>Digestive and Liver Disease</i> , 2012, 44, 183-184.	0.4	2
377	â€œPancProâ€ as a tool for selecting families eligible for pancreatic cancer screening: An Italian study of incident cases. <i>Digestive and Liver Disease</i> , 2012, 44, 585-588.	0.4	17
378	Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. <i>Digestive and Liver Disease</i> , 2012, 44, 945-951.	0.4	85

#	ARTICLE	IF	CITATIONS
379	Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 570-577.	0.5	158
380	Poorly differentiated resectable pancreatic cancer: Is upfront resection worthwhile?. <i>Surgery</i> , 2012, 152, S112-S119.	1.0	28
381	Neuroendocrine tumor disease: an evolving landscape. <i>Endocrine-Related Cancer</i> , 2012, 19, R163-R185.	1.6	133
382	ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors. <i>Neuroendocrinology</i> , 2012, 95, 120-134.	1.2	478
383	SILS cholecystectomy, early experience of a single institution: pilot study of 21 cases. <i>Updates in Surgery</i> , 2012, 64, 145-148.	0.9	1
384	Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. <i>British Journal of Surgery</i> , 2012, 99, 1234-1240.	0.1	65
385	Laparoscopic rectal resection for severe endometriosis of the mid and low rectum: technique and operative results. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 1035-1040.	1.3	76
386	Cystic Pancreatic Tumors. , 2012, , 111-133.		0
387	Hyperinsulinemic hypoglycemia associated with ectopic Cushing's syndrome due to a pancreatic endocrine tumor in a Type 2 diabetes mellitus patient: Clinical implications of a rare association. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 175-179.	1.8	8
388	Laparoscopic Colorectal Surgery for Bowel Endometriosis With Transvaginal Resection and Specimen Extraction: Perioperative Results in 40 Consecutive Patients. <i>Gastroenterology</i> , 2011, 140, S-1030.	0.6	0
389	Surgical Treatment of Pancreatic Tumors in Childhood and Adolescence: Uncommon Neoplasms with Favorable Outcome. <i>Pancreatology</i> , 2011, 11, 383-389.	0.5	32
390	Treatment trends in metastatic pancreatic cancer patients: Is it time to change?. <i>Digestive and Liver Disease</i> , 2011, 43, 225-230.	0.4	8
391	Early Postoperative Outcomes After Laparoscopic Segmental Colorectal Resection for Endometriosis: The Impact of Surgical Experience. <i>Gastroenterology</i> , 2011, 140, S-1030.	0.6	0
392	Advanced Digestive Endocrine Tumors: Prognostic Factors Analysis and Patients Stratification According to Metastatic Status. <i>Gastroenterology</i> , 2011, 140, S-873.	0.6	0
393	Clinical and Patient-Reported Outcomes After Pancreatoduodenectomy for Different Diseases. <i>Pancreas</i> , 2011, 40, 938-945.	0.5	49
394	Total pancreatectomy: Indications, different timing, and perioperative and long-term outcomes. <i>Surgery</i> , 2011, 149, 79-86.	1.0	109
395	Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. <i>Surgery</i> , 2011, 150, 75-82.	1.0	306
396	Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors. <i>BMC Cancer</i> , 2011, 11, 351.	1.1	65

#	ARTICLE	IF	CITATIONS
397	B-Cell Lymphoma Presenting as Acute Pancreatitis. <i>Pancreatology</i> , 2011, 11, 553-556.	0.5	13
398	Splenic Artery Invasion in Pancreatic Adenocarcinoma of the Body and Tail: A Novel Prognostic Parameter for Patient Selection. <i>Annals of Surgical Oncology</i> , 2011, 18, 3608-3614.	0.7	40
399	Laparoscopic ileocecal resection for bowel endometriosis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 1257-1262.	1.3	23
400	Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases. <i>Langenbeck's Archives of Surgery</i> , 2011, 396, 313-321.	0.8	36
401	Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression. <i>Journal of Clinical Oncology</i> , 2011, 29, 2372-2377.	0.8	261
402	Presentation and Outcome of Pancreaticoduodenal Endocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome. <i>Neuroendocrinology</i> , 2011, 94, 58-65.	1.2	39
403	Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review. <i>Neuroendocrinology</i> , 2011, 93, 223-229.	1.2	103
404	An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?. <i>Anti-Cancer Drugs</i> , 2010, 21, 459-464.	0.7	8
405	Invasive Intraductal Papillary Mucinous Carcinomas of the Pancreas. <i>Annals of Surgery</i> , 2010, 251, 477-482.	2.1	69
406	Acoustic Radiation Force Impulse Ultrasound Imaging of Pancreatic Cystic Lesions. <i>Pancreas</i> , 2010, 39, 939-940.	0.5	10
407	Parenchyma-Preserving Resections for Small Nonfunctioning Pancreatic Endocrine Tumors. <i>Annals of Surgical Oncology</i> , 2010, 17, 1621-1627.	0.7	153
408	Parenchyma-sparing resections for pancreatic neoplasms. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 782-787.	1.4	67
409	Imaging of neuroendocrine gastroenteropancreatic tumours. <i>Radiologia Medica</i> , 2010, 115, 1047-1064.	4.7	36
410	Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1645-1651.	0.8	279
411	MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. <i>Endocrine-Related Cancer</i> , 2010, 17, 771-783.	1.6	135
412	Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway. <i>Journal of Clinical Oncology</i> , 2010, 28, 245-255.	0.8	497
413	Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. <i>Modern Pathology</i> , 2010, 23, 824-833.	2.9	396
414	Clinicopathological Features of Pancreatic Endocrine Tumors: A Prospective Multicenter Study in Italy of 297 Sporadic Cases. <i>American Journal of Gastroenterology</i> , 2010, 105, 1421-1429.	0.2	125

#	ARTICLE	IF	CITATIONS
415	Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v55-v58.	0.6	134
416	ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2010, 91, 341-350.	1.2	65
417	Pancreatic Cystic Endocrine Tumors: A Different Morphological Entity Associated with a Less Aggressive Behavior. <i>Neuroendocrinology</i> , 2010, 92, 246-251.	1.2	71
418	Mucin-Producing Neoplasms of the Pancreas: An Analysis of Distinguishing Clinical and Epidemiologic Characteristics. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 213-219.e4.	2.4	289
419	Autoimmune pancreatitis: A challenging diagnostic puzzle for clinicians. <i>Digestive and Liver Disease</i> , 2010, 42, 92-98.	0.4	25
420	Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: A position paper from the Italian Registry. <i>Digestive and Liver Disease</i> , 2010, 42, 597-605.	0.4	38
421	Improving cytological diagnosis of pancreatic cysts: Is it clinically necessary or just the latest fashion?. <i>Digestive and Liver Disease</i> , 2010, 42, 844-845.	0.4	4
422	Italian consensus guidelines for chronic pancreatitis. <i>Digestive and Liver Disease</i> , 2010, 42, S381-S406.	0.4	140
423	Extent of surgical resections for intraductal papillary mucinous neoplasms. <i>World Journal of Gastrointestinal Surgery</i> , 2010, 2, 347.	0.8	37
424	Risk Factors for Sporadic Pancreatic Endocrine Tumors. <i>American Journal of Gastroenterology</i> , 2009, 104, 3034-3041.	0.2	52
425	Autoimmune Pancreatitis: Differences Between the Focal and Diffuse Forms in 87 Patients. <i>American Journal of Gastroenterology</i> , 2009, 104, 2288-2294.	0.2	226
426	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:Echocardiography. <i>Neuroendocrinology</i> , 2009, 90, 190-193.	1.2	57
427	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2009, 90, 203-208.	1.2	38
428	Somatostatin Receptor Subtypes 2 and 5 Are Associated with Better Survival in Well-Differentiated Endocrine Carcinomas. <i>Neuroendocrinology</i> , 2009, 89, 223-230.	1.2	51
429	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation. <i>Neuroendocrinology</i> , 2009, 90, 227-233.	1.2	128
430	Identification of a Novel Antibody Associated with Autoimmune Pancreatitis. <i>New England Journal of Medicine</i> , 2009, 361, 2135-2142.	13.9	327
431	Contrast-Enhanced Sonography of Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>American Journal of Roentgenology</i> , 2009, 192, 424-430.	1.0	84
432	âœParaduodenalâœPancreatitis: Results of Surgery on 58 Consecutives Patients from a Single Institution. <i>World Journal of Surgery</i> , 2009, 33, 2664-2669.	0.8	96

#	ARTICLE	IF	CITATIONS
433	Resectable Pancreatic Adenocarcinoma: Is the Enhancement Pattern at Contrast-Enhanced Ultrasonography a Pre-Operative Prognostic Factor?. <i>Ultrasound in Medicine and Biology</i> , 2009, 35, 1929-1937.	0.7	47
434	Resectable Pancreatic Cancer: Who Really Benefits From Resection?. <i>Annals of Surgical Oncology</i> , 2009, 16, 3316-3322.	0.7	143
435	Middle-preserving pancreatectomy for multicentric body-sparing lesions of the pancreas. <i>American Journal of Surgery</i> , 2009, 198, e49-e53.	0.9	27
436	Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. <i>Digestive and Liver Disease</i> , 2009, 41, 49-55.	0.4	73
437	Chronic pancreatitis: Report from a multicenter Italian survey (PanCroInfAISP) on 893 patients. <i>Digestive and Liver Disease</i> , 2009, 41, 311-317.	0.4	136
438	Is CA 19-9 a screening marker?. <i>Digestive and Liver Disease</i> , 2009, 41, 325-327.	0.4	8
439	Insulinoma—new insights into an old disease. <i>Nature Reviews Endocrinology</i> , 2009, 5, 300-302.	4.3	13
440	Pancreatoblastoma in Adults: A Review of the Literature. <i>Pancreatology</i> , 2009, 9, 73-80.	0.5	52
441	Endocrine Neoplasms of the Pancreas: Pathologic and Genetic Features. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 350-364.	1.2	78
442	Cancer of the Exocrine Pancreas: Surgery and Multimodal Treatment. , 2009, , 89-100.		0
443	Clinical Aspect of Complications: Features and Prognoses. <i>Medical Radiology</i> , 2009, , 261-267.	0.0	0
444	Surgical and Interventional Perspective in Chronic Pancreatitis. <i>Medical Radiology</i> , 2009, , 383-390.	0.0	0
445	Pancreatic Endocrine Tumors. , 2009, , 163-175.		0
446	Prognostic Relevance of Lymph Node Ratio and Number of Resected Nodes after Curative Resection of Ampulla of Vater Carcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 3178-3186.	0.7	82
447	Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary. <i>Neuroendocrinology</i> , 2008, 87, 47-62.	1.2	285
448	Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. <i>Annals of Oncology</i> , 2008, 19, 903-908.	0.6	200
449	Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Tumour/Carcinoma of the Appendix and Goblet Cell Carcinoma. <i>Neuroendocrinology</i> , 2008, 87, 20-30.	1.2	119
450	Resectable Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2008, 37, 265-268.	0.5	24

#	ARTICLE	IF	CITATIONS
451	Mucinous Cystic Neoplasm of the Pancreas is Not an Aggressive Entity. <i>Annals of Surgery</i> , 2008, 247, 571-579.	2.1	407
452	Procedura terapeutica. , 2008, , 67-81.		0
453	Comparison of Contrast-Enhanced Sonography and MRI in Displaying Anatomic Features of Cystic Pancreatic Masses. <i>American Journal of Roentgenology</i> , 2007, 189, 1435-1442.	1.0	83
454	Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate?. <i>Gut</i> , 2007, 56, 1086-1090.	6.1	235
455	Smoking Cessation at the Clinical Onset of Chronic Pancreatitis and Risk of Pancreatic Calcifications. <i>Pancreas</i> , 2007, 35, 320-326.	0.5	71
456	Middle Pancreatectomy. <i>Annals of Surgery</i> , 2007, 246, 69-76.	2.1	222
457	Low Expression of ARHI Is Associated with Shorter Progression-Free Survival in Pancreatic Endocrine Tumors. <i>Neoplasia</i> , 2007, 9, 181-182.	2.3	36
458	Usefulness of Technetium-99m Hexamethylpropylene Amine Oxime-Labeled Leukocyte Scintigraphy to Detect Pancreatic Necrosis in Patients with Acute Pancreatitis. <i>Pancreatology</i> , 2007, 7, 459-469.	0.5	46
459	Branch-Duct Intraductal Papillary Mucinous Neoplasms: Observations in 145 Patients Who Underwent Resection. <i>Gastroenterology</i> , 2007, 133, 72-79.	0.6	422
460	A case of intraductal papillary mucinous tumour following recurrent attacks of pancreatitis lasting 26 years. <i>Digestive and Liver Disease</i> , 2007, 39, 585-588.	0.4	0
461	Amylase Value in Drains After Pancreatic Resection as Predictive Factor of Postoperative Pancreatic Fistula. <i>Annals of Surgery</i> , 2007, 246, 281-287.	2.1	270
462	Ampullary somatostatinomas and jejunal gastrointestinal stromal tumor in a patient with Von Recklinghausen's disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 2761.	1.4	31
463	Pancreatic insufficiency after different resections for benign tumours. <i>British Journal of Surgery</i> , 2007, 95, 85-91.	0.1	219
464	Enucleation of pancreatic neoplasms. <i>British Journal of Surgery</i> , 2007, 94, 1254-1259.	0.1	169
465	Clinical and biological behavior of pancreatic solid pseudopapillary tumors: Report on 31 consecutive patients. <i>Journal of Surgical Oncology</i> , 2007, 95, 304-310.	0.8	87
466	Anastomotic leakage in pancreatic surgery. <i>Hpb</i> , 2007, 9, 8-15.	0.1	65
467	Ultrasonography of the pancreas. 7. Intraoperative imaging. <i>Abdominal Imaging</i> , 2007, 32, 200-206.	2.0	29
468	The determinant factors of recurrence following resection for ductal pancreatic cancer. <i>JOP: Journal of the Pancreas</i> , 2007, 8, 132-40.	1.5	24

#	ARTICLE	IF	CITATIONS
469	Isolated blunt duodenal trauma: delayed diagnosis and favorable outcome with "quadruple tube" decompression. JOP: Journal of the Pancreas, 2007, 8, 617-20.	1.5	12
470	Pancreatic metastasis from leiomyosarcoma of the broad ligament of the uterus. Lancet Oncology, The, 2006, 7, 94-95.	5.1	32
471	Intraductal Papillary Mucinous Neoplasms and Chronic Pancreatitis. Pancreatology, 2006, 6, 626-634.	0.5	46
472	Rare Functioning Pancreatic Endocrine Tumors. Neuroendocrinology, 2006, 84, 189-195.	1.2	124
473	International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas. Pancreatology, 2006, 6, 17-32.	0.5	1,805
474	Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). Journal of Endocrinological Investigation, 2006, 29, 563-567.	1.8	31
475	Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. European Journal of Cancer, 2006, 42, 477-484.	1.3	69
476	Duodenal duplication cyst causing severe pancreatitis: Imaging findings and pathological correlation. World Journal of Gastroenterology, 2006, 12, 1630.	1.4	48
477	How useful is somatostatin at reducing complications associated with pancreatic surgery?. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 134-135.	1.7	0
478	Long-term Results of Frey's Procedure for Chronic Pancreatitis: A Longitudinal Prospective Study on 40 Patients. Journal of Gastrointestinal Surgery, 2006, 10, 504-510.	0.9	41
479	Open Pancreaticogastrostomy After Pancreaticoduodenectomy: A Pilot Study. Journal of Gastrointestinal Surgery, 2006, 10, 1072-1080.	0.9	30
480	TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 395-401.	1.4	1,403
481	Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma. Neuroendocrinology, 2006, 84, 196-211.	1.2	241
482	MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical Behavior. Journal of Clinical Oncology, 2006, 24, 4677-4684.	0.8	752
483	Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma. Neuroendocrinology, 2006, 84, 183-188.	1.2	248
484	Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Annals of Oncology, 2006, 17, 461-466.	0.6	120
485	Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocrine-Related Cancer, 2006, 13, 1213-1221.	1.6	87
486	Radiotherapy and chemotherapy in pancreatic cancer. Topical issues and future perspectives. JOP: Journal of the Pancreas, 2006, 7, 122-30.	1.5	1

#	ARTICLE	IF	CITATIONS
487	Surgical strategy in the treatment of pancreatic neuroendocrine tumors. JOP: Journal of the Pancreas, 2006, 7, 150-6.	1.5	16
488	Pancreatic Pathology. , 2005, , 335-347.		18
489	Value of regional lymphadenectomy in pancreatic cancer. Hpb, 2005, 7, 87-92.	0.1	13
490	Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. British Journal of Surgery, 2005, 81, 265-269.	0.1	203
491	Mucinous cystic carcinoma of the pancreas: a unique cell line and xenograft model of a preinvasive lesion. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 239-245.	1.4	18
492	Contrast-Enhanced Ultrasonography of Small Solid Pseudopapillary Tumors of the Pancreas. Journal of Ultrasound in Medicine, 2005, 24, 849-854.	0.8	25
493	Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocrine-Related Cancer, 2005, 12, 1083-1092.	1.6	360
494	Contrast-enhanced ultrasonography better identifies pancreatic tumor vascularization than helical CT. Pancreatology, 2005, 5, 398-402.	0.5	86
495	Reconstruction by Pancreaticojejunostomy Versus Pancreaticogastrostomy Following Pancreatectomy. Annals of Surgery, 2005, 242, 767-773.	2.1	398
496	Intraductal papillary mucinous tumors of the pancreas. Surgical treatment: at what point should we stop?. JOP: Journal of the Pancreas, 2005, 6, 112-7.	1.5	6
497	Contrast-Enhanced Ultrasonography in the Characterization of Pancreatic Mucinous Cystadenoma. Journal of Ultrasound in Medicine, 2004, 23, 1125-1129.	0.8	27
498	Allelotype of ampulla of Vater cancer: highly frequent involvement of chromosome 11. Journal of Cancer Research and Clinical Oncology, 2004, 130, 339-345.	1.2	5
499	Neuroendocrine pancreatic tumor. Abdominal Imaging, 2004, 29, 246-258.	2.0	96
500	Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. Journal of Endocrinological Investigation, 2004, 27, 6-11.	1.8	104
501	Discussion on prophylactic antibiotic treatment in patients with predicted severe pancreatitis: A placebo-controlled, double-blind trial. Gastroenterology, 2004, 127, 1015-1016.	0.6	11
502	Role of unlabelled somatostatin analogues in the prevention of complications after elective pancreatic and peripancreatic surgery: a critical review. Digestive and Liver Disease, 2004, 36, S121-S127.	0.4	1
503	Prospective multicentre survey on acute pancreatitis in Italy (ProInf-AISP): results on 1005 patients. Digestive and Liver Disease, 2004, 36, 205-211.	0.4	99
504	Pancreatic Fistula Rate after Pancreatic Resection. Digestive Surgery, 2004, 21, 54-59.	0.6	278

#	ARTICLE	IF	CITATIONS
505	A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 1200-1210.	13.9	2,442
506	Maldi-TOF analysis of portal sera of pancreatic cancer patients: identification of diabetogenic and antidiabetogenic peptides. <i>Clinica Chimica Acta</i> , 2004, 343, 119-127.	0.5	9
507	Prophylactic pylorus-preserving gastric transposition in unresectable carcinoma of the pancreatic head. <i>American Journal of Surgery</i> , 2004, 187, 564-566.	0.9	4
508	Main-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Annals of Surgery</i> , 2004, 239, 678-687.	2.1	681
509	Pancreatic Decompression in Chronic Pancreatitis. , 2004, , 474-478.		0
510	Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and metastatic pancreatic cancer: a phase I-II study. <i>Anticancer Research</i> , 2004, 24, 2107-12.	0.5	6
511	Management of 100 Consecutive Cases of Pancreatic Serous Cystadenoma: Wait for Symptoms and See at Imaging or Vice Versa?. <i>World Journal of Surgery</i> , 2003, 27, 319-323.	0.8	195
512	Sonography versus helical CT in identification and staging of pancreatic ductal adenocarcinoma. <i>Journal of Clinical Ultrasound</i> , 2003, 31, 175-182.	0.4	53
513	High recurrence rate after atypical resection for pancreatic metastases from renal cell carcinoma. <i>British Journal of Surgery</i> , 2003, 90, 555-559.	0.1	137
514	Outcome of Open Necrosectomy in Acute Pancreatitis. <i>Pancreatology</i> , 2003, 3, 128-132.	0.5	29
515	Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial. <i>Surgery</i> , 2003, 134, 766-771.	1.0	264
516	Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade?. <i>Digestive and Liver Disease</i> , 2003, 35, 421-427.	0.4	12
517	Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy. <i>Annals of Oncology</i> , 2003, 14, 586-591.	0.6	26
518	Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. <i>American Journal of Gastroenterology</i> , 2003, 98, 2435-2439.	0.2	137
519	Contrast-Enhanced Ultrasonographic Detection of Small Pancreatic Insulinoma. <i>Journal of Ultrasound in Medicine</i> , 2003, 22, 413-417.	0.8	45
520	Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: preliminary study. <i>Digestive and Liver Disease</i> , 2002, 34, 127-132.	0.4	10
521	Absence of mutations in the transforming growth factor- β 2 inducible early gene 1, TIEG1, in pancreatic cancer. <i>Cancer Letters</i> , 2002, 183, 179-183.	3.2	11
522	Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. <i>Journal of Surgical Oncology</i> , 2002, 81, 45-53.	0.8	84

#	ARTICLE	IF	CITATIONS
523	Sex chromosome anomalies in pancreatic endocrine tumors. <i>International Journal of Cancer</i> , 2002, 98, 532-538.	2.3	58
524	Dpc4 is expressed in virtually all primary and metastatic pancreatic endocrine carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 155-159.	1.4	14
525	Changes in pancreatic resection for chronic pancreatitis over 28 years in a single institution. <i>British Journal of Surgery</i> , 2002, 87, 428-433.	0.1	22
526	Clinicopathological features and treatment of intraductal papillary mucinous tumour of the pancreas. <i>British Journal of Surgery</i> , 2002, 88, 376-381.	0.1	163
527	Non-traumatic abdominal emergencies: imaging and intervention in acute pancreatic conditions. <i>European Radiology</i> , 2002, 12, 2407-2434.	2.3	26
528	The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, Ca 19-9, Ca 125, Ca 15-3. <i>Langenbeck's Archives of Surgery</i> , 2002, 387, 281-285.	0.8	46
529	Ampulla of Vater cancers: T-stage and histological subtype but not Dpc4 expression predict prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 441, 19-24.	1.4	15
530	Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology study Section of the Italian Society of Gastroenterology (SIGE). <i>Digestive and Liver Disease</i> , 2001, 33, 217-221.	0.4	29
531	Management of Complications after Pancreaticoduodenectomy in a High Volume Centre: Results on 150 Consecutive Patients / with Invited Commentary. <i>Digestive Surgery</i> , 2001, 18, 453-458.	0.6	235
532	Molecular Characterization of Pancreatic Serous Microcystic Adenomas. <i>American Journal of Pathology</i> , 2001, 158, 317-321.	1.9	95
533	Infection prevention in necrotizing pancreatitis: an old challenge with new perspectives. <i>Journal of Hospital Infection</i> , 2001, 49, 4-8.	1.4	17
534	Symptomatic stone in the duodenum after gastrectomy. <i>Surgery</i> , 2001, 129, 238-239.	1.0	6
535	Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. <i>Lancet, The</i> , 2001, 358, 1576-1585.	6.3	1,019
536	In vivo Octreotide Administration Acutely Reduces Exocrine Granule Size in the Human Pancreas. <i>Pancreatology</i> , 2001, 1, 30-35.	0.5	8
537	Previous Cholecystectomy, Gastrectomy, and Diabetes Mellitus are not Crucial Risk Factors for Pancreatic Cancer in Patients with Chronic Pancreatitis. <i>Pancreas</i> , 2001, 23, 364-367.	0.5	12
538	Prophylaxis for septic complications in acute necrotizing pancreatitis. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2001, 8, 211-215.	2.0	20
539	Successful xenografting of cryopreserved primary pancreatic cancers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 438, 154-158.	1.4	34
540	Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 177-181.	1.5	95

#	ARTICLE	IF	CITATIONS
541	Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization. <i>European Radiology</i> , 2001, 11, 1175-1183.	2.3	91
542	Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. <i>British Journal of Cancer</i> , 2001, 84, 253-262.	2.9	181
543	Alcohol Intake, Cigarette Smoking, and Body Mass Index in Patients with Alcohol-associated Pancreatitis. <i>Journal of Clinical Gastroenterology</i> , 2000, 31, 314-317.	1.1	22
544	A novel germline mutation, P48T, in the CDKN2A/p16 gene in a patient with pancreatic carcinoma. <i>Human Mutation</i> , 2000, 16, 447-448.	1.1	13
545	Pancreatic acinar carcinoma shows a distinct pattern of chromosomal imbalances by comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 2000, 28, 294-299.	1.5	27
546	Cancer of the ampulla of Vater: chromosome 17p allelic loss is associated with poor prognosis. <i>Gut</i> , 2000, 46, 842-848.	6.1	40
547	A single-institution experience with fistulojejunostomy for external pancreatic fistulas. <i>American Journal of Surgery</i> , 2000, 179, 203-206.	0.9	37
548	Role of Chemoembolization in Synchronous Liver Metastases from Pancreatic Endocrine Tumours. <i>Digestive Surgery</i> , 1999, 16, 32-38.	0.6	33
549	Assessment and Treatment of Severe Pancreatitis. <i>Digestion</i> , 1999, 60, 5-8.	1.2	6
550	Early Detection of Pancreatic Cancer following the Diagnosis of Chronic Pancreatitis. <i>Digestion</i> , 1999, 60, 554-561.	1.2	29
551	Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1303-1311.	1.1	225
552	Incidence of Cancer in The Course of Chronic Pancreatitis. <i>American Journal of Gastroenterology</i> , 1999, 94, 1253-1260.	0.2	172
553	Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. , 1998, 186, 41-50.		70
554	Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. <i>Gastroenterology</i> , 1998, 115, 1513-1517.	0.6	197
555	Long-Term Follow-up of Patients with Chronic Pancreatitis in Italy. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 880-889.	0.6	79
556	Surgical Treatment of Pancreatic Metastases from Renal Cell Carcinomas. <i>Digestive Surgery</i> , 1998, 15, 241-246.	0.6	41
557	To what extent is surgery superior to endoscopic therapy in the management of chronic pancreatitis?. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1998, 30, 571-9.	0.5	2
558	The role of surgery in the major early complications of severe acute pancreatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 131-136.	0.8	10

#	ARTICLE	IF	CITATIONS
559	Does the Extent of Lymphatic Resection Affect the Outcome in Pancreatic Cancer?. <i>Digestion</i> , 1997, 58, 536-541.	1.2	8
560	Pancreatic cystic manifestations in von Hippel-Lindau disease. <i>International Journal of Gastrointestinal Cancer</i> , 1997, 22, 101-109.	0.4	34
561	Evaluation of UICC TNM classification for pancreatic cancer. <i>International Journal of Gastrointestinal Cancer</i> , 1997, 21, 111-118.	0.4	10
562	Pain relapses in the first 10 years of chronic pancreatitis. <i>American Journal of Surgery</i> , 1996, 171, 565-569.	0.9	37
563	Antimicrobial activity of human pancreatic juice and its interaction with antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 1996, 40, 2099-2105.	1.4	23
564	Risk of death from acute pancreatitis. <i>International Journal of Gastrointestinal Cancer</i> , 1996, 19, 15-24.	0.4	87
565	Prospective study of the detection and treatment of small tumors of the head of the pancreas. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 1995, 2, 347-351.	2.0	5
566	Effectiveness of gabexate mesilate in acute pancreatitis. <i>Digestive Diseases and Sciences</i> , 1995, 40, 734-738.	1.1	80
567	Cancer of the Papilla of Vater: Preoperative Cryostatic Examination of Endoscopic Biopsies to Reduce Risk and Save Time and Money. <i>Digestive Surgery</i> , 1995, 12, 256-258.	0.6	0
568	Role of somatostatin and somatostatin analogues in the treatment of gastrointestinal diseases: prevention of complications after pancreatic surgery.. <i>Gut</i> , 1994, 35, S20-S22.	6.1	23
569	Behavior of antibiotics during human necrotizing pancreatitis. <i>Antimicrobial Agents and Chemotherapy</i> , 1994, 38, 830-836.	1.4	123
570	Role of Somatostatin and Its Analogues in Gastrointestinal Fistulas, Ascites and Pancreatic Pseudocysts. <i>Digestive Surgery</i> , 1994, 11, 451-455.	0.6	3
571	Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). <i>International Journal of Gastrointestinal Cancer</i> , 1993, 14, 117-124.	0.4	49
572	Antibacterial and mezlocillin-enhancing activity of pure human pancreatic fluid. <i>International Journal of Gastrointestinal Cancer</i> , 1991, 10, 293-297.	0.4	17
573	Early graft injurie, after pancreatic transplantation insyngeneic rats. <i>International Journal of Gastrointestinal Cancer</i> , 1991, 8, 345-353.	0.4	3
574	Pancreatic abscess and other pus-harboring collections related to pancreatitis: A review of 108 cases. <i>World Journal of Surgery</i> , 1990, 14, 505-511.	0.8	50
575	Retroperitoneal and peritoneal drainage and lavage in the treatment of severe necrotizing pancreatitis. <i>Surgery, Gynecology & Obstetrics</i> , 1990, 170, 197-203.	0.6	44
576	Pancreaticoduodenal Graft in the Rat: An Original Microsurgical Technique. <i>European Surgical Research</i> , 1989, 21, 162-167.	0.6	9

#	ARTICLE	IF	CITATIONS
577	Ofloxacin penetration into bile and pancreatic juice. Journal of Antimicrobial Chemotherapy, 1989, 23, 805-807.	1.3	18
578	Continuous peritoneal dialysis in acute experimental pancreatitis in dogs. International Journal of Gastrointestinal Cancer, 1989, 5, 69-75.	0.4	13
579	Ciprofloxacin Penetration in Pancreatic Juice. Chemotherapy, 1987, 33, 397-401.	0.8	26
580	Penetration of mezlocillin into pancreatic Juice. Journal of Antimicrobial Chemotherapy, 1986, 17, 397-397.	1.3	14
581	Rifampicin concentrations in pancreatic juice. Journal of Antimicrobial Chemotherapy, 1985, 16, 129-130.	1.3	8
582	Diagnosis and Differential Diagnosis of Pancreatic Cystic Tumors. , 0, , 488-496.		0
583	Neuroendocrine Tumors. , 0, , 564-668.		0
584	Double-stapled anastomosis versus mucosectomy and handsewn anastomosis in ileal pouch-anal anastomosis for ulcerative colitis or familial adenomatous polyposis. The Cochrane Library, 0, , .	1.5	0
585	Double-stapled anastomosis versus mucosectomy and handsewn anastomosis in ileal pouch-anal anastomosis for ulcerative colitis or familial adenomatous polyposis. The Cochrane Library, 0, , .	1.5	0
586	Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: a case-matched analysis. Endocrine Abstracts, 0, , .	0.0	0